Context Therapeutics 2023 annual meeting: auditor ratified, reverse stock split not approved

Context Therapeutics Inc.

Ratification of CohnReznick LLP as independent auditor for FY2023 approved with 9,827,096 for, 232,432 against, 109,961 abstentions.
Proposal to amend charter for reverse stock split (1:2 to 1:50) failed: 7,809,550 for, 2,326,090 against, 33,849 abstentions, not reaching majority of outstanding shares.
Quorum of 63.69% (10,169,489 shares) present at May 31, 2023 annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Context Therapeutics Inc. shareholders approved Ratification of CohnReznick LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

Proposal 1. To ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Context Therapeutics Inc. shareholders rejected Amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-50 at the 2023-05-31 meeting.

Proposal: reverse split
Outcome: failed
Meeting: 2023-05-31

Exact text from the filing

Proposal 2. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of its outstanding common stock at a reverse stock split ratio ranging from any whole number between 1-for-2 and 1-for-50, subject to and as determined by the Board of Directors.

View on SEC.gov

Browse all shareholder votes →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-23-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.